Evidence map›Paper›PMID 35649263›Full record

ArticleOrganic letters2022

Genome Mining and Metabolomics Unveil Pseudonochelin: A Siderophore Containing 5-Aminosalicylate from a Marine-Derived

Fan Zhang, René F Ramos Alvarenga, Kurt Throckmorton, Shaurya Chanana, Doug R Braun, Jen Fossen, Miao Zhao, Sue McCrone, Mary Kay Harper, Scott R Rajski and 4 more

Open access · greenAbstract read
In one paragraph

Article in Organic letters, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Fan ZhangPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
René F Ramos AlvarengaPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.ORCID 0000-0002-0311-7090
Kurt ThrockmortonDepartment of Bacteriology, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Shaurya ChananaPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Doug R BraunPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Jen FossenDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.ORCID 0000-0002-2413-5618
Miao ZhaoDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Sue McCronePharmacy Practice Division, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Mary Kay HarperDepartment of Medicinal Chemistry, University of Utah, Salt Lake City, Utah 84112, United States.
Scott R RajskiPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Warren E RosePharmacy Practice Division, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
David R AndesDepartment of Medicine, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.
Michael G ThomasDepartment of Bacteriology, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States.
Tim S BugniPharmaceutical Sciences Division, University of Wisconsin-Madison, Madison, Wisconsin 53705, United States.ORCID 0000-0002-4502-3084
University of Wisconsin–Madison · USUniversity of Utah · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Christian Capitini · 1985 to 2026
$142.6M
Novel antimicrobials targeting MDR pathogens from animal microbial symbiontsU19AI142720 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI ANDES, DAVID R · 2019 to 2023
$30.1M
Metabolomics driven discovery of drug leads from symbiotic bacteriaU19AI109673 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI ANDES, DAVID R, CURRIE, CAMERON ROBERT · 2014 to 2018
$16.2M
TR&D 3: TECHNOLOGY DEVELOPMENT FOR NMR STUDIES OF SMALL MOLECULES (METABOLOMICS, NATURAL PRODUCTS, METABOLITE-PROTEIN INTERACTIONS) pp.537-585 P41GM103399 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BUTCHER, SAMUEL E · 2012 to 2019
$9.4M
NCI NIH HHS P30 CA014520NIAID NIH HHS U19 AI109673NIAID NIH HHS U19 AI142720NIGMS NIH HHS P41 GM103399
6 · The paper itself

Abstract

Pseudonochelin (

Indexed as

MesalamineSiderophoresBacteriaMetabolomicsMultigene FamilyPseudonocardiaMesalamineSiderophores

Identifiers

PMID35649263
PMCPMC9270686
OpenAlexW4281725122

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.